Recursion Pharmaceuticals Inc (RXRX) saw downtrend of -0.41% in the recent trading with $4.83 being its most recent. The current price level -60.92% lower than the highest price of $12.36 marked by the stock while trading over the past 52-weeks, whereas it is 27.44% higher than the lowest price of $3.79 the company dropped to over past 52-weeks. The latest news story on RXRX appeared in (Motley Fool) under the title “When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.50 for the stock.
Recursion Pharmaceuticals Inc Earnings – What Happened With RXRX
Coming around sales and income figures on RXRX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Recursion Pharmaceuticals Inc (RXRX) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of -2.15% for net revenue.
RXRX – Recursion Pharmaceuticals Inc Stock Earnings Estimates
The perspective of Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.33 for stock’s EPS in the current quarter. Recursion Pharmaceuticals Inc (RXRX) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of -2.15% for net revenue. Company’s EPS for the last quarter was -0.34.
Recursion Pharmaceuticals Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 425.48 million. RXRX does have institutional investors; and they hold 53.76% of the stock.
As on 2024-06-30, ARK INVESTMENT MANAGEMENT LLC was the top most holder in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) with an ownership of 28.14 million shares of the company or 11.6199 of the stake worth $211.07 million. The filing also reveals BAILLIE GIFFORD & CO as the second largest holder in the company with a control over 10.9787 of the outstanding shares. Its stake is worth $199.42 million for having 26.59 million shares in hand.
VANGUARD GROUP INC also came holding a key position in the company during the recent quarter and it now holds 8.9004 of the outstanding shares. With this there are now 430.0 institutions which have possession in RXRX’s shares.
Key Metrics for RXRX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Recursion Pharmaceuticals Inc has a debt to equity ratio of 0.10.
